If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,548.00    -6.00 (-0.39%)
Bid:
1,544.00
Ask:
1,547.00
Spread: 3.00 (0.194%)
Market Cap: £3.26b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 Dec 2007 14:05

Hikma Pharmaceuticals Plc17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the sale of 320,000 ordinary sharesof 10 pence each in the capital of the Company, received by him pursuant to anexercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executedon 14 December 2007. The shares sold represented 0.187% of the outstanding sharecapital of the Company, and following the sale Mr Darwazah remains interested in1,706,506 ordinary shares, representing 0.999% of the share capital of theCompany. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relates toDTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Jun 20143:11 pmRNSDirector/PDMR Shareholding
10th Jun 20145:13 pmRNSTotal Voting Rights
29th May 20149:45 amRNSDirector/PDMR Shareholding
29th May 20149:40 amRNSDirector/PDMR Shareholding
28th May 201412:00 pmRNSAcquisition
27th May 20149:53 amRNSDirector/PDMR Shareholding
15th May 20143:05 pmRNSResults of AGM
15th May 20147:00 amRNSInterim Management Statement
6th May 20141:03 pmRNSDirector/PDMR Shareholding
17th Apr 20144:41 pmRNSAnnual Information Update
14th Apr 20145:28 pmRNSDirector/PDMR Shareholding
7th Apr 20145:28 pmRNSBlocklisting Interim Review
7th Apr 20144:27 pmRNSTotal Voting Rights
2nd Apr 20147:00 amRNSSuccessful resolution to US FDA warning letter
24th Mar 201410:23 amRNSDirector/PDMR Shareholding
12th Mar 20147:10 amRNSDirectorate Change
12th Mar 20147:00 amRNSFinal Results
27th Feb 20142:35 pmRNSNotification of major interests in shares
21st Feb 201410:24 amRNSBlock Listing of Shares
14th Feb 20147:00 amRNSTrading Statement
30th Dec 20139:50 amRNSDirector/PDMR Shareholding
20th Dec 20134:23 pmRNSDirector/PDMR Shareholding
20th Dec 20131:58 pmRNSDirector/PDMR Shareholding
16th Dec 20137:00 amRNSTotal Voting Rights
13th Dec 20137:00 amRNSHolding(s) in Company
20th Nov 20137:00 amRNSRe Agreement
11th Nov 20134:55 pmRNSDirector/PDMR Shareholding
8th Nov 20133:04 pmRNSDirector/PDMR Shareholding
8th Nov 20137:00 amRNSInterim Management Statement
25th Oct 20134:13 pmRNSDirector/PDMR Shareholding
23rd Oct 201311:40 amRNSHolding(s) in Company
18th Oct 20134:55 pmRNSDirector/PDMR Shareholding
4th Oct 20132:01 pmRNSDividend Declaration
1st Oct 201311:27 amRNSBlocklisting Interim Review
1st Oct 201311:22 amRNSTotal Voting Rights
18th Sep 20137:00 amRNSHikma entering Ethiopian pharmaceutical market
2nd Sep 20133:06 pmRNSTransaction in Own Shares
29th Aug 201311:10 amRNSTransaction in Own Shares
21st Aug 20137:00 amRNSInterim Results
31st Jul 20133:41 pmRNSDirector/PDMR Shareholding
19th Jul 20139:40 amRNSTotal Voting Rights
8th Jul 20137:00 amRNSTrading Statement
5th Jul 20134:21 pmRNSHolding(s) in Company
1st Jul 20137:00 amRNSSigning of Exclusive Agreement with Theravance
20th Jun 20133:16 pmRNSDirector/PDMR Shareholding
3rd Jun 201311:24 amRNSTotal Voting Rights
28th May 20135:24 pmRNSHolding(s) in Company
23rd May 20134:59 pmRNSDirector/PDMR Shareholding
21st May 20133:36 pmRNSDirector/PDMR Shareholding
20th May 20139:42 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.